

Extraordinary General Meeting in Forward Pharma A/S (In voluntary liquidation)

PROXY/VOTING BY CORRESPONDENCE FORM

for use at the extraordinary general meeting in Forward Pharma A/S (In voluntary liquidation) on 26 November 2025 at 18:00 (CET).

Name: _____

Address: _____

(Please use CAPITAL LETTERS)

I/we hereby authorise by proxy/submit written votes (voting by correspondence) in accordance with the indications below:

Please check off field A), B), C) or D):

- A) Proxy is granted to a named third party (**deadline on 21 November 2025 end of day (CET)**):

Name: _____

Address: _____

(Please use CAPITAL LETTERS)

or

- B) Proxy is granted to the liquidator (with a right of substitution) to vote in accordance with the liquidator's proposals as set out in the table below (**deadline on 21 November 2025 end of day (CET)**).

or

- C) Check-the-box Proxy is granted to the liquidator (with a right of substitution) to vote as stated below. Please check off the boxes "FOR", "AGAINST" or "ABSTAIN" to indicate your vote (**deadline on 21 November 2025 end of day (CET)**).

or

- D) Written votes (voting by correspondence) are submitted as stated below. Written votes cannot be withdrawn. Please check off the boxes "FOR", "AGAINST" or "ABSTAIN" to indicate your vote (**deadline on 25 November 2025 end of day (CET)**).

Agenda

The complete agenda is included in the notice to convene the extraordinary general meeting.

If the votes attaching to a shareholder's shares are cast differently in relation to a specific agenda item, this shall be indicated in the table below.

AGENDA ITEMS	FOR	AGAINST	ABSTAIN	RECOMMENDATION FROM THE LIQUIDATOR
(b) Presentation of the audited final liquidation accounts for approval.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				
(c) Resolution regarding final liquidation and distribution of liquidation proceeds.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				
(d) Authorization of the chairperson of the meeting.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				

If the form is only dated and signed, it will be considered a proxy to the liquidator to vote in accordance with the recommendations of the liquidator as stated above.

If the form is only partially completed, votes will be cast in accordance with the recommendations of the liquidator as stated above with respect to the non-ticked off boxes.

The proxy/voting by correspondence is valid for the number of shares that the undersigned holds on the record date, 19 November 2025 end of day (CET), as calculated based on (i) the number of shares registered in the company's register of shareholders and (ii) notifications of ownership received by the company but not yet registered in the company's register of shareholders.

Date: _____ 2025

Name:

Title:

Name:

Title:

*The dated and signed form, if used as a proxy (box A-C above), must reach Forward Pharma A/S (In voluntary liquidation) no later than **21 November 2025 end of day (CET)**, and, if used for written votes (voting by correspondence) (box D above), no later than **25 November 2025 end of day (CET)**. In each case the form must be sent either by email (kbo@mazanti.dk) or by ordinary mail to Mazanti-Andersen Advokatpartnerselskab, Amaliegade 10, 1265 Copenhagen K, Denmark, Attn. Kristian Bojsen.*